LU90069I2 - Lercanidipine et ses sels et dérivés pharmaceutiquement acceptables (Zanidip) - Google Patents

Lercanidipine et ses sels et dérivés pharmaceutiquement acceptables (Zanidip)

Info

Publication number
LU90069I2
LU90069I2 LU90069C LU90069C LU90069I2 LU 90069 I2 LU90069 I2 LU 90069I2 LU 90069 C LU90069 C LU 90069C LU 90069 C LU90069 C LU 90069C LU 90069 I2 LU90069 I2 LU 90069I2
Authority
LU
Luxembourg
Prior art keywords
zanidip
lercanidipine
derivatives
pharmaceutically acceptable
acceptable salts
Prior art date
Application number
LU90069C
Other languages
English (en)
French (fr)
Original Assignee
Recordati Chem Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10556581&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90069(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Recordati Chem Pharm filed Critical Recordati Chem Pharm
Publication of LU90069I2 publication Critical patent/LU90069I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/56—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups bound to carbon atoms of six-membered aromatic rings and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
LU90069C 1984-02-14 1997-05-28 Lercanidipine et ses sels et dérivés pharmaceutiquement acceptables (Zanidip) LU90069I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB848403866A GB8403866D0 (en) 1984-02-14 1984-02-14 Diphenylalkylaminoalkyl esters

Publications (1)

Publication Number Publication Date
LU90069I2 true LU90069I2 (fr) 1997-07-23

Family

ID=10556581

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90069C LU90069I2 (fr) 1984-02-14 1997-05-28 Lercanidipine et ses sels et dérivés pharmaceutiquement acceptables (Zanidip)

Country Status (29)

Country Link
US (3) US4705797A (en, 2012)
EP (1) EP0153016B1 (en, 2012)
JP (1) JPS60199874A (en, 2012)
KR (1) KR910005231B1 (en, 2012)
AR (1) AR240804A1 (en, 2012)
AT (1) ATE52772T1 (en, 2012)
AU (1) AU570534B2 (en, 2012)
BR (1) BR1101167A (en, 2012)
CA (1) CA1277666C (en, 2012)
DE (2) DE10199007I2 (en, 2012)
DK (1) DK160985C (en, 2012)
DZ (1) DZ748A1 (en, 2012)
EG (1) EG17772A (en, 2012)
ES (1) ES8602664A1 (en, 2012)
FI (1) FI83954C (en, 2012)
GB (1) GB8403866D0 (en, 2012)
GR (1) GR850363B (en, 2012)
HU (1) HU194171B (en, 2012)
IE (1) IE57715B1 (en, 2012)
IL (1) IL74238A (en, 2012)
LU (1) LU90069I2 (en, 2012)
MX (1) MX156874A (en, 2012)
NL (1) NL970025I2 (en, 2012)
NO (2) NO166123C (en, 2012)
NZ (1) NZ210866A (en, 2012)
PH (1) PH20725A (en, 2012)
PT (1) PT79963B (en, 2012)
SG (1) SG48590G (en, 2012)
ZA (1) ZA85656B (en, 2012)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561213B2 (en) * 1983-06-02 1987-04-30 Teijin Limited 1, 4-dihydropyridine derivative
US4994476A (en) * 1984-10-31 1991-02-19 Bristol-Myers Company Dihydropyridin-3,5-dicarboxylates incorporating aryloxypropanolamine moieties
DE3677319D1 (de) * 1985-10-22 1991-03-07 Sanwa Kagaku Kenkyusho Co Pharmazeutische 1,4-dihydropyridinderivate, ihre salze und herstellung.
DE3633496A1 (de) * 1986-10-02 1988-04-14 Hoechst Ag Kombination von angiotensin-converting-enzyme-hemmern mit calciumantagonisten sowie deren verwendung in arzneimitteln
JPH02149563A (ja) * 1988-11-30 1990-06-08 Nisshin Flour Milling Co Ltd ２−ハロエトキシカルボニル基を含有する１，４−ジヒドロピリジン誘導体の製造法
IT1279529B1 (it) * 1995-05-12 1997-12-16 Recordati Chem Pharm Procedimento di preparazione ed uso degli enantiomeri (s) di derivati 1,4-diidropiridinici per il trattamento dell'insufficienza cardiaca
IT1274480B (it) * 1995-05-12 1997-07-17 Recordati Chem Pharm Procedimento migliorato per la preparazione della lercanidipina cloridrato
US5767136A (en) * 1995-05-12 1998-06-16 Recordati, S.A. Chemical And Pharmaceutical Company 1,4-Dihydropyridines useful for prevention or reduction of atherosclerotic lesions on arterial walls
IT1275532B (it) * 1995-07-14 1997-08-07 Recordati Chem Pharm Uso di derivati 1,4-diidropiridinici per la prevenzione e la terapia della degenerazione aterosclerotica della parete arteriosa
US5696139A (en) * 1995-05-12 1997-12-09 Recordati S.A., Chemical And Pharmaceutical Company Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure
US5851636A (en) * 1995-12-29 1998-12-22 Lantec Products, Inc. Ceramic packing with channels for thermal and catalytic beds
RU2200315C2 (ru) * 2001-05-25 2003-03-10 Чалкин Станислав Филиппович Устройство для анализа жидких сред люминесцентным методом
ITMI20011727A1 (it) * 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Solvati della lercanidipina cloridrato e nuove forme cristalline della lercanidipina cloridrato ottenute da essi
US6852737B2 (en) 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
ITMI20011726A1 (it) * 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Forme polimorfe della lercanidipina cloridrato
DE60336485D1 (de) 2002-08-19 2011-05-05 Pfizer Kombinationstherapie gegen hyperproliferative erkrankungen
US20040147566A1 (en) * 2002-10-16 2004-07-29 Amedeo Leonardi Lisinopril/lercanidipine combination therapy
US20050101640A1 (en) * 2002-10-16 2005-05-12 Recordati Ireland Limited Lisinopril/lercanidipine combination therapy
US7923467B2 (en) 2003-05-30 2011-04-12 Ranbaxy Laboratories, Inc. Substituted pyrrole derivatives and their use as HMG-CO inhibitors
WO2005107374A2 (en) * 2004-05-07 2005-11-17 Sun Pharmaceutical Industries Limited A process for the preparation of 1,4-dihydropyridine-3,5-dicarboxylic acid derivative
RU2007106714A (ru) * 2004-07-26 2008-09-10 Байер Шеринг Фарма Аг (De) Лечение легочной гипертензии путем ингаляции илопростата с препаратом микрочастиц
TW200613275A (en) * 2004-08-24 2006-05-01 Recordati Ireland Ltd Lercanidipine salts
US20060134212A1 (en) * 2004-09-02 2006-06-22 Forest Laboratories, Inc. Lercanidipine immediate release compositions
US20060165789A1 (en) * 2004-09-09 2006-07-27 Forest Laboratories, Inc. Lercanidipine modified release compositions
US20060165788A1 (en) * 2004-09-09 2006-07-27 Wattanaporn Abramowitz Lercanidipine pH dependent pulsatile release compositions
KR100616276B1 (ko) * 2004-09-21 2006-08-28 일동제약주식회사 2,엔-디메틸-엔-(3,3-디페닐프로필)-1-아미노-2-프로판올의제조방법
TW200616681A (en) * 2004-10-05 2006-06-01 Recordati Ireland Ltd Lercanidipine capsules
KR100651212B1 (ko) * 2004-10-27 2006-12-01 제일약품주식회사 무정형 레르카니디핀의 제조방법
IL165525A0 (en) * 2004-12-02 2006-01-15 Motivan Ltd Intermediates and a process for the manufacturing for antihypertensive dihydropyridine derivative suitable for pharmaceutical compositions
AR052918A1 (es) * 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
AR053023A1 (es) * 2005-02-25 2007-04-18 Recordati Ireland Ltd Base libre de lercanidipina, metodos para su preparacion y composiciones farmaceuticas que las contienen
KR100638171B1 (ko) * 2005-03-25 2006-10-26 건일제약 주식회사 2,ｎ-디메틸-ｎ-(3,3-디페닐프로필)-1-아미노-2-프로판올의제조방법
EP1891009B1 (en) 2005-06-15 2009-10-14 Hetero Drugs Limited A novel process for the preparation of lercanidipine
BRPI0616169B8 (pt) 2005-09-16 2021-05-25 Glenmark Pharmaceuticals Ltd cloridrato de lercanidipina na forma polimorfa v, composição farmacêutica compreendendo dito composto e processos para preparação de cloridrato de lercanidipina
WO2007054969A2 (en) * 2005-09-21 2007-05-18 Torrent Pharmaceuticals Limited Process for the preparation of lercanidipine and amorphous form of lercanidipine hydrochloride
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
EP2351569B1 (en) 2005-10-26 2012-08-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
ATE551059T1 (de) 2005-10-26 2012-04-15 Asahi Kasei Pharma Corp Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie
US8026377B2 (en) 2005-11-08 2011-09-27 Ranbaxy Laboratories, Limited Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
WO2007120135A1 (en) * 2006-04-17 2007-10-25 Forest Laboratories, Inc. Lercanidipine immediate release composition
DE602006003877D1 (de) * 2006-05-24 2009-01-08 Cf Pharma Ltd Verfahren zur Herstellung von Lercanipidin
PT2046745E (pt) * 2006-08-04 2014-01-15 Recordati Ireland Ltd Processo para preparação de cloridrato de lercanidipina amorfo
US20080175872A1 (en) * 2006-09-28 2008-07-24 Osmotica Corp. Controlled Release Dosage Form Containing Lercanidipine and a Performance-enhancing Acid
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
EP2114883A4 (en) * 2006-12-29 2010-09-08 Dongwoo Syntech Co Ltd PROCESS FOR THE PREPARATION OF LERCANIDIPINE HYDROCHLORIDE
KR100848935B1 (ko) 2007-05-16 2008-07-29 주식회사 대희화학 생체 촉매 효소를 이용한 광학 선택적 가수분해방법
SI2585051T2 (sl) 2010-06-23 2020-07-31 Krka, D.D., Novo Mesto Farmacevtske oralne odmerne oblike,ki obsegajo lerkanidipin in enalapril in njune farmacevtsko sprejemljive soli
WO2012037665A1 (en) 2010-09-24 2012-03-29 Oral Delivery Technology Ltd. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
EP2444394A1 (en) 2010-10-21 2012-04-25 Alembic Pharmaceuticals Limited Process for the preparation of amorphous form of lercanidipine HCI
WO2012085249A2 (en) 2010-12-24 2012-06-28 Krka, D.D., Novo Mesto Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts
WO2012123966A1 (en) 2011-03-04 2012-09-20 Arch Pharmalabs Limited Process for the preparation of 4 -substituted -1, 4-dihydropyridines
AU2014255381A1 (en) 2013-04-17 2015-10-08 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN113574055B (zh) 2019-01-18 2024-07-23 阿斯利康(瑞典)有限公司 Pcsk9抑制剂及其使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985758A (en) * 1973-02-20 1976-10-12 Yamanouchi Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives
JPS5762257A (en) * 1980-10-03 1982-04-15 Yoshitomi Pharmaceut Ind Ltd 1,4-dihydropyridine-3,5-dicarboxylic acid ester or its salt
NZ201395A (en) * 1981-07-30 1987-02-20 Bayer Ag Pharmaceutical compositions containing 1,4-dihydropyridines and certain of these dihydropyridines
DE3269219D1 (en) * 1981-11-17 1986-03-27 Fisons Plc Dihydropyridines, methods for their production and their formulation and use as pharmaceuticals
ATE50987T1 (de) * 1982-05-10 1990-03-15 Takeda Chemical Industries Ltd Dihydropyridinderivate, deren herstellung und verwendung.
AU561213B2 (en) * 1983-06-02 1987-04-30 Teijin Limited 1, 4-dihydropyridine derivative
NO854021L (no) * 1984-10-26 1986-04-28 Bayer Ag 1,4-dihydropyridin-hydroksyaminer og fremgangsmaate til fremstilling derav.
GB8503424D0 (en) * 1985-02-11 1985-03-13 Ici Plc Heterocyclic derivatives

Also Published As

Publication number Publication date
US4705797A (en) 1987-11-10
EP0153016A3 (en) 1985-10-02
KR850005826A (ko) 1985-09-26
BR1101167A (pt) 2004-08-17
ES540385A0 (es) 1985-11-16
FI83954B (fi) 1991-06-14
HU194171B (en) 1988-01-28
NL970025I1 (nl) 1997-09-01
DK63085D0 (da) 1985-02-12
IE57715B1 (en) 1993-03-10
DK160985B (da) 1991-05-13
DE10199007I2 (de) 2003-01-09
NO850521L (no) 1985-08-15
NO166123B (no) 1991-02-25
SG48590G (en) 1990-08-17
FI83954C (fi) 1991-09-25
IE850280L (en) 1985-08-14
ZA85656B (en) 1985-08-28
NO2000011I1 (no) 2000-10-17
DE10199007I1 (de) 2001-04-12
DE3577703D1 (de) 1990-06-21
NL970025I2 (nl) 1998-01-05
AU3868985A (en) 1985-09-12
KR910005231B1 (ko) 1991-07-24
NO166123C (no) 1991-06-05
JPS60199874A (ja) 1985-10-09
AR240804A2 (es) 1991-02-28
PH20725A (en) 1987-03-30
IL74238A (en) 1988-07-31
AR240804A1 (es) 1991-02-28
IL74238A0 (en) 1985-05-31
PT79963B (en) 1986-11-10
FI850535L (fi) 1985-08-15
PT79963A (en) 1985-03-01
CA1277666C (en) 1990-12-11
EP0153016A2 (en) 1985-08-28
ATE52772T1 (de) 1990-06-15
GR850363B (en, 2012) 1986-02-06
DK63085A (da) 1985-08-15
DK160985C (da) 1991-11-04
US4772621A (en) 1988-09-20
ES8602664A1 (es) 1985-11-16
US4968832A (en) 1990-11-06
AU570534B2 (en) 1988-03-17
EP0153016B1 (en) 1990-05-16
EG17772A (en) 1991-08-30
GB8403866D0 (en) 1984-03-21
NZ210866A (en) 1988-07-28
MX156874A (es) 1988-10-08
JPH0517908B2 (en, 2012) 1993-03-10
DZ748A1 (fr) 2004-09-13
HUT37399A (en) 1985-12-28
FI850535A0 (fi) 1985-02-08

Similar Documents

Publication Publication Date Title
LU90069I2 (fr) Lercanidipine et ses sels et dérivés pharmaceutiquement acceptables (Zanidip)
LU91039I2 (fr) Proteq flu et ses dérivés pharmaceutiquement acceptables
LU90829I2 (fr) Tepoxalin-zubrin et ses d-riv-s pharmaceutiquement acceptables
LU90484I2 (fr) Novorapid - insuline asparte et ses sels et derives pharmaceutiquement acceptables
LU90219I2 (fr) Tolcapone et ses dérivés pharmaceutiquement acceptables (TASMAR)
LU88736I2 (fr) Cefquinome et ses dérivés pharmaceutiquement acceptables (COBACTAN)
LU90769I2 (fr) Capecitabine et ses d-riv-es pharmaceutiquement acceptables (xeloda)
LU90138I2 (fr) Etoposide phosphate et ses sels et dérivés pharmaceutiquement acceptables (etopophos)
LU88750I2 (fr) VENLAFAXINE et ses dérivés pharmaceutiquement acceptables
LU91205I2 (fr) Ciclesonide et ses dérivés pharmaceutiquement acceptables (alvesco)
LU90736I2 (fr) Agenerase-amprenavir et ses d-riv-s pharmaceutiquement acceptables
LU91452I2 (fr) "Mycafungine et ses sels pharmaceutiquement acceptables(MYCAMINEr)"
LU91147I2 (fr) Pemetrexed et ses sels pharmaceutiquement acceptables.
LU90244I2 (fr) Glimepiride et ses sels physiologiquement acceptables (amarylle r)
LU90211I2 (fr) Miglitol et ses sels et dérivés pharmaceutiquement acceptables (diastabol)
NO941211D0 (no) Farmakologisk aktive pyrimidinforbindelser og fremgangsmåte for deres fremstilling
LU91072I2 (fr) Eplerenone et ses sels pharmaceutiquement acceptables - INSPRA
FI892682L (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten 1-deoksinojirimysiinijohdannaisten valmistamiseksi
NO2001009I1 (no) Kvetiapin og farmasøytisk akseptable salter derav
LU88334I2 (fr) 9-(1,3-Dihydroxy-2-propoxyméthyl) guanine et ses sels pharmaceutiquement acceptables.
LU91197I2 (fr) Azoxystrobin et folpel et leurs dérivés pharmaceutiquement acceptables (QUADRIS MAX).
FI935920A7 (fi) Oksatsolidiinijohdannaiset ja niiden farmaseuttisesti hyväksyttävät suolat
LU90345I2 (fr) Ramipril + Felodipine et les sels physiologuiquement acceptables de ceux-ci (TAZKO)
MC2263A1 (fr) Aminobenzodiazepines et leurs sels pharmaceutiquement acceptables
DK264785D0 (da) Galenisk retardpraeparat